S&P 500   4,124.32 (-0.95%)
DOW   34,008.62 (-0.43%)
QQQ   304.59 (-1.71%)
AAPL   151.62 (-1.96%)
MSFT   268.78 (+0.46%)
META   185.35 (-3.27%)
GOOGL   99.14 (-7.90%)
AMZN   99.60 (-2.46%)
TSLA   198.79 (+1.01%)
NVDA   223.02 (+0.58%)
NIO   10.70 (-2.01%)
BABA   105.91 (+0.39%)
AMD   85.51 (-0.47%)
T   19.08 (-0.88%)
F   13.45 (+0.00%)
MU   60.55 (-2.54%)
CGC   2.77 (-1.77%)
GE   81.82 (-0.35%)
DIS   110.90 (-0.65%)
AMC   5.75 (-6.96%)
PFE   43.75 (+0.37%)
PYPL   80.11 (-3.75%)
NFLX   361.07 (-0.52%)
S&P 500   4,124.32 (-0.95%)
DOW   34,008.62 (-0.43%)
QQQ   304.59 (-1.71%)
AAPL   151.62 (-1.96%)
MSFT   268.78 (+0.46%)
META   185.35 (-3.27%)
GOOGL   99.14 (-7.90%)
AMZN   99.60 (-2.46%)
TSLA   198.79 (+1.01%)
NVDA   223.02 (+0.58%)
NIO   10.70 (-2.01%)
BABA   105.91 (+0.39%)
AMD   85.51 (-0.47%)
T   19.08 (-0.88%)
F   13.45 (+0.00%)
MU   60.55 (-2.54%)
CGC   2.77 (-1.77%)
GE   81.82 (-0.35%)
DIS   110.90 (-0.65%)
AMC   5.75 (-6.96%)
PFE   43.75 (+0.37%)
PYPL   80.11 (-3.75%)
NFLX   361.07 (-0.52%)
S&P 500   4,124.32 (-0.95%)
DOW   34,008.62 (-0.43%)
QQQ   304.59 (-1.71%)
AAPL   151.62 (-1.96%)
MSFT   268.78 (+0.46%)
META   185.35 (-3.27%)
GOOGL   99.14 (-7.90%)
AMZN   99.60 (-2.46%)
TSLA   198.79 (+1.01%)
NVDA   223.02 (+0.58%)
NIO   10.70 (-2.01%)
BABA   105.91 (+0.39%)
AMD   85.51 (-0.47%)
T   19.08 (-0.88%)
F   13.45 (+0.00%)
MU   60.55 (-2.54%)
CGC   2.77 (-1.77%)
GE   81.82 (-0.35%)
DIS   110.90 (-0.65%)
AMC   5.75 (-6.96%)
PFE   43.75 (+0.37%)
PYPL   80.11 (-3.75%)
NFLX   361.07 (-0.52%)
S&P 500   4,124.32 (-0.95%)
DOW   34,008.62 (-0.43%)
QQQ   304.59 (-1.71%)
AAPL   151.62 (-1.96%)
MSFT   268.78 (+0.46%)
META   185.35 (-3.27%)
GOOGL   99.14 (-7.90%)
AMZN   99.60 (-2.46%)
TSLA   198.79 (+1.01%)
NVDA   223.02 (+0.58%)
NIO   10.70 (-2.01%)
BABA   105.91 (+0.39%)
AMD   85.51 (-0.47%)
T   19.08 (-0.88%)
F   13.45 (+0.00%)
MU   60.55 (-2.54%)
CGC   2.77 (-1.77%)
GE   81.82 (-0.35%)
DIS   110.90 (-0.65%)
AMC   5.75 (-6.96%)
PFE   43.75 (+0.37%)
PYPL   80.11 (-3.75%)
NFLX   361.07 (-0.52%)
NASDAQ:TNXP

Tonix Pharmaceuticals - TNXP Stock Forecast, Price & News

$1.27
+0.09 (+7.71%)
(As of 02/8/2023 12:27 PM ET)
Add
Compare
Today's Range
$1.15
$1.33
50-Day Range
$0.29
$1.30
52-Week Range
$0.29
$11.52
Volume
2.88 million shs
Average Volume
6.68 million shs
Market Capitalization
$73.13 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.85

Tonix Pharmaceuticals MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
963.9% Upside
$12.85 Price Target
Short Interest
Bearish
9.84% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.32mentions of Tonix Pharmaceuticals in the last 14 days
Based on 3 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($3.37) to ($1.60) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.00 out of 5 stars

Medical Sector

569th out of 1,029 stocks

Pharmaceutical Preparations Industry

272nd out of 504 stocks

TNXP stock logo

About Tonix Pharmaceuticals (NASDAQ:TNXP) Stock

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company headquartered in Chatham, New Jersey. The company was founded in 2007 and then later went public in 2013. Tonix Pharmaceuticals is led by Seth Lederman who has been CEO since co-founding the company. Mr. Lederman was an Associate Professor at Columbia University for more than 2 decades before venturing into the private sector. Tonix Pharmaceuticals is his second venture, the first was bought out after developing an effective treatment for colorectal cancer. The company operates through three facilities located in Massachusetts, Maryland, and Montana.

The two east-coast facilities are the R&D center and the Advanced Development Center while manufacturing is located in Montana. The Maryland facility is rated BSL-2 with some areas rated BSL-3 which allows for the handling of live viruses. The Massachusetts facility is intended to enhance the company’s R&D and analytics capabilities as well as facilitate vaccine production at the clinical trial scale. The Montana facility will support Phase III trials as well as the mass production of approved treatments.

Tonix Pharmaceuticals focuses on discovering, acquiring, developing, and licensing therapeutics and diagnostics to treat and prevent human disease and alleviate suffering across a wide spectrum of ailments and treatments. Among them is COVID-19 for which the company has several products in development.

Its portfolio includes immunology, rare disease, infectious disease, and central nervous system (CNS) product candidates. The types of diseases the company targets are widely occurring but hard to treat so breakthroughs of any kind could be significant sources of income. The company has several candidates in pre-clinical and clinical trials with two standouts that are on track for FDA approval. Resilient, a treatment for Fibromyalgia, and Prevail, a treatment for long-COVID, entered Phase III and Phase II trials in 2022.

The immunology portfolio includes treatments for organ transplant rejection, autoimmunity, and cancer, and several in this group have shown efficacy against multiple indications. The company’s infectious disease pipeline includes several promising treatments for viruses afflicting the world today. The TNX-80 vaccine is intended to prevent smallpox and monkeypox while TNX-1840 and TNX-1850 are live virus vaccines to fight COVID-19, as will TNX-3500 and TNX-102, which are small molecule antiviral drugs.

Tonix Pharmaceuticals CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric, and addiction including Resilient, which is in mid-Phase 3 development for the management of fibromyalgia. Other products in the pipeline are TNX-1900 which is in development for the prevention of migraine headaches and TNX-1300 which is designed to treat cocaine intoxication.

Receive TNXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tonix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TNXP Stock News Headlines

Without Graphite, There Would Be ZERO EV Batteries!
Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.
Without Graphite, There Would Be ZERO EV Batteries!
Investors constantly hear that lithium is the key to powering the transition to green energy. Truth is, today's EV batteries contain more graphite in volume than any other essential ingredients.
Recap: Tonix Pharmaceuticals Q3 Earnings
Tonix Pharmaceuticals GAAP EPS of -$0.69 beats by $0.33
Tonix Pharmaceuticals Holding Corp. (TNXP)
See More Headlines
Receive TNXP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Tonix Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

TNXP Company Calendar

Last Earnings
11/07/2021
Today
2/08/2023
Next Earnings (Estimated)
3/13/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:TNXP
Employees
73
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.85
High Stock Price Forecast
$19.20
Low Stock Price Forecast
$6.50
Forecasted Upside/Downside
+911.0%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-92,290,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$14.08 per share

Miscellaneous

Free Float
56,385,000
Market Cap
$73.13 million
Optionable
Optionable
Beta
2.09

Key Executives

  • Seth LedermanSeth Lederman
    Chairman, President & Chief Executive Officer
  • Jessica Edgar Morris
    Chief Operating Officer
  • Bradley Saenger
    Chief Financial Officer & Treasurer
  • Gregory M. Sullivan
    Secretary & Chief Medical Officer
  • Bruce L. Daugherty
    Executive Vice President-Research













TNXP Stock - Frequently Asked Questions

Should I buy or sell Tonix Pharmaceuticals stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Tonix Pharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" TNXP shares.
View TNXP analyst ratings
or view top-rated stocks.

What is Tonix Pharmaceuticals' stock price forecast for 2023?

2 analysts have issued 12-month price objectives for Tonix Pharmaceuticals' shares. Their TNXP share price forecasts range from $6.50 to $19.20. On average, they anticipate the company's share price to reach $12.85 in the next year. This suggests a possible upside of 989.0% from the stock's current price.
View analysts price targets for TNXP
or view top-rated stocks among Wall Street analysts.

How have TNXP shares performed in 2023?

Tonix Pharmaceuticals' stock was trading at $0.3898 at the start of the year. Since then, TNXP stock has increased by 202.7% and is now trading at $1.18.
View the best growth stocks for 2023 here
.

Are investors shorting Tonix Pharmaceuticals?

Tonix Pharmaceuticals saw a increase in short interest in January. As of January 15th, there was short interest totaling 5,660,000 shares, an increase of 68.5% from the December 31st total of 3,360,000 shares. Based on an average daily volume of 6,540,000 shares, the short-interest ratio is currently 0.9 days. Approximately 9.8% of the company's shares are short sold.
View Tonix Pharmaceuticals' Short Interest
.

When is Tonix Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023.
View our TNXP earnings forecast
.

How were Tonix Pharmaceuticals' earnings last quarter?

Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) released its quarterly earnings data on Sunday, November, 7th. The company reported ($1.60) EPS for the quarter, topping the consensus estimate of ($2.24) by $0.64.

When did Tonix Pharmaceuticals' stock split?

Tonix Pharmaceuticals shares reverse split before market open on Tuesday, May 17th 2022. The 1-32 reverse split was announced on Tuesday, May 17th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, May 17th 2022. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

What other stocks do shareholders of Tonix Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tonix Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), Vaxart (VXRT), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Rite Aid (RAD), Heat Biologics (HTBX), Matinas BioPharma (MTNB), Bionano Genomics (BNGO), VBI Vaccines (VBIV) and ADMA Biologics (ADMA).

What is Tonix Pharmaceuticals' stock symbol?

Tonix Pharmaceuticals trades on the NASDAQ under the ticker symbol "TNXP."

How do I buy shares of Tonix Pharmaceuticals?

Shares of TNXP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tonix Pharmaceuticals' stock price today?

One share of TNXP stock can currently be purchased for approximately $1.18.

How much money does Tonix Pharmaceuticals make?

Tonix Pharmaceuticals (NASDAQ:TNXP) has a market capitalization of $67.90 million. The company earns $-92,290,000.00 in net income (profit) each year or ($5.7438) on an earnings per share basis.

How can I contact Tonix Pharmaceuticals?

Tonix Pharmaceuticals' mailing address is 509 MADISON AVENUE SUITE 1608, NEW YORK NY, 10022. The official website for the company is www.tonixpharma.com. The company can be reached via phone at (212) 980-9155, via email at investor.relations@tonixpharma.com, or via fax at 212-923-5700.

This page (NASDAQ:TNXP) was last updated on 2/8/2023 by MarketBeat.com Staff